Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 4/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.70 |
| ▸ | KDM6B | O15054 | 1/20 | 0.70 |
| ▸ | KDM4A | O75164 | 1/20 | 0.70 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.70 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.69 |
| ▸ | HPGD | P15428 | 2/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.69 |
| ▸ | POLB | P06746 | 1/20 | 0.69 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.69 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.63 |
| ▸ | KDR | P35968 | 4/20 | 0.59 |
| ▸ | FLT1 | P17948 | 3/20 | 0.59 |
| ▸ | PLK1 | P53350 | 1/20 | 0.58 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.57 |
| ▸ | CDC7 | O00311 | 2/20 | 0.56 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.56 |
| ▸ | ABL1 | P00519 | 1/20 | 0.54 |
| ▸ | EGFR | P00533 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2691864 | 0.88 | HSD17B10 (0.81) | KDM4CKDM4EKDM6BKDM4AKDM4D | |
| SCHEMBL5718299 | 0.87 | CDC7 (0.64) | KDM4CKDM4EKDM6BKDM4AKDM4D | |
| SCHEMBL5718602 | 0.85 | KDM4C (0.56) | KDM4CKDM4EKDM6BKDM4AKDM4D | |
| SCHEMBL12204389 | 0.85 | MAPK1 (0.63) | KDM4CKDM4EKDM6BKDM4AKDM4D | |
| SCHEMBL4174105 | 0.84 | KDR (0.60) | KDM4CKDM4EKDM6BKDM4AKDM4D | |
| SCHEMBL1714819 | 0.84 | KDM4C (0.85) | KDM4CKDM4EKDM6BKDM4AKDM4D | |
| SCHEMBL5718586 | 0.84 | KDM4C (0.66) | KDM4CKDM4EKDM6BKDM4AKDM4D | |
| SCHEMBL4977683 | 0.84 | KDR (0.71) | POLBKDRFLT1ABL1EGFR | |
| SCHEMBL1714816 | 0.83 | ALDH1A1 (0.71) | KDM4CKDM4EKDM6BKDM4AKDM4D | |
| SCHEMBL3261522 | 0.83 | ALDH1A1 (0.63) | KDM4CKDM4EKDM6BKDM4AKDM4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1906155-A | Novel hydroxamic acid esters and pharmaceutical use thereof | LEO PHARMA AS (DK) | 2007-01-31 | — | — | CN | claimed |
| WO-2011140599-A1 | CHEMICAL COMPOUND ARRAYS USEFUL FOR DETECTING BACTERIAL PEPTIDES | MONASH UNIVERSITY (AU) | 2011-11-17 | — | — | WO | disclosed |
| US-8034811-B2 | Hydroxamic acid esters and pharmaceutical use thereof | LEO PHARMA A/S (DK) | 2011-10-11 | — | — | US | disclosed |
| US-8034811-B2 | Hydroxamic acid esters and pharmaceutical use thereof | LEO PHARMA A/S (DK) | 2011-10-11 | — | — | US | disclosed |
| US-8034811-B2 | Hydroxamic acid esters and pharmaceutical use thereof | LEO PHARMA A/S (DK) | 2011-10-11 | — | — | US | disclosed |
| EP-1697312-B1 | HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF | LEO PHARMA AS (DK) | 2011-07-20 | — | — | EP | disclosed |
| EP-1697312-B1 | HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF | LEO PHARMA AS (DK) | 2011-07-20 | — | — | EP | disclosed |
| CN-1906155-B | Novel hydroxamic acid ester derivant and pharmaceutical use thereof | LEO PHARMA AS | 2010-06-23 | — | — | CN | disclosed |
| US-7479491-B2 | Azanthranylalkyl and -cycloalkyl amides and their use as VEGF receptor inhibitors | NOVARTIS AG (CH) | 2009-01-20 | — | — | US | disclosed |
| US-20080293696-A1 | 2-Aminoarylcarboxamides Useful as Cancer Chemotherapeutic Agents | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-11-27 | — | — | US | disclosed |
| US-20030176469-A1 | Anthranylalkyl and cycloalkyl amides and use thereof as vegf receptor inhibitors | NOVARTIS AG (CH) | 2003-09-18 | — | — | US | disclosed |
| US-20030064992-A1 | N-aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | ALTMANN KARL-HEINZ (CH) | 2003-04-03 | — | — | US | disclosed |
| US-6448277-B2 | ANTITUOR AGENTS, ANTICARCINOGENIC AGENTS | NOVARTIS AG (CH) | 2002-09-10 | — | — | US | disclosed |
| US-20020019414-A1 | N-aryl(thio)anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2002-02-14 | — | — | US | disclosed |
| WO-2001085719-A9 | ORTHO-SUBSTITUTED ANTHRANILIC ACID AMIDES AND THEIR USE AS MEDICAMENTS | SCHERING AG (DE) | 2001-12-27 | — | — | WO | disclosed |
| CN-1325384-A | Anthranilic acid amides and the use thereof as medicaments | SCHERING AG (DE) | 2001-12-05 | — | — | CN | disclosed |
| EP-1129075-A1 | N-ARYL(THIO)ANTHRANILIC ACID AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS VEGF RECEPTOR TYROSINE KINASE INHIBITORS | Novartis AG (CH) | 2001-09-05 | — | — | EP | disclosed |
| EP-1129074-A2 | ANTRHRANILIC ACID AMIDES AND THE USE THEREOF AS MEDICAMENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-09-05 | — | — | EP | disclosed |
| WO-2000027820-A1 | N-ARYL(THIO)ANTHRANILIC ACID AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS VEGF RECEPTOR TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2000-05-18 | — | — | WO | disclosed |
| WO-2000027819-A2 | ANTRHRANILIC ACID AMIDES AND THE USE THEREOF AS MEDICAMENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030064992-A1 | N-aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | AXL, TYRO3, NR2E3 | KDM4C 4478/4885KDM4E 3338/4885KDM6B 3115/4885 |
| US-20080293696-A1 | 2-Aminoarylcarboxamides Useful as Cancer Chemotherapeutic Agents | ABCC3, HCCS, ABCC2 | KDM4C 568/4885KDM4E 975/4885KDM6B 1624/4885 |
| US-20020019414-A1 | N-aryl(thio)anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | AXL, TYRO3, KDR | KDM4C 4411/4885KDM4E 3319/4885KDM6B 2782/4885 |
| US-20030176469-A1 | Anthranylalkyl and cycloalkyl amides and use thereof as vegf receptor inhibitors | KDR, FLT1, VEGFA | KDM4C 4512/4885KDM4E 3646/4885KDM6B 3908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.